Latest Conference Articles

New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Ansell on Waldenstrom Macroglobulinemia Types

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia

Noted Researcher Sees ERT as Remarkable Beginning

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Same Mission, New Role for Genzyme Executive: Head of Rare Diseases Committed to Patients

Rogerio Vivaldi, MD, has vivid memories of the first patient with Gaucher disease ever treated in Brazil with enzyme replacement therapy.

Lysosomal Storage Disorders: Marking Milestones and Moving Forward

The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.

Dr. Grabowski Explains the Effects of Enzyme Therapy

Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy

Dr. Mistry Discusses His Experience With Gaucher Disease

Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease

Dr. Mato on the Benefits of the JTCC Retrospective Trial

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Photos From the 2011 ASH Annual Meeting and Exposition

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

Ponatinib Continues March to Potential Front-line Use in CML

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Feldman Discusses the Difficulties of Rare Lymphomas

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Photos From the 2011 San Antonio Breast Cancer Symposium

A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

Dr. José Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.